Cargando…

Increased oral sodium chloride intake in humans amplifies selectively postprandial GLP‐1 but not GIP, CCK, and gastrin in plasma

Human studies have demonstrated that physiologically relevant changes in circulating glucagon‐like peptide‐1 (GLP‐1) elicit a rapid increase in renal sodium excretion when combined with expansion of the extracellular fluid volume. Other studies support the involvement of various gastrointestinal hor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Asmar, Ali, Cramon, Per K., Asmar, Meena, Simonsen, Lene, Sorensen, Charlotte M., Madsbad, Sten, Moro, Cedric, Hartmann, Bolette, Rehfeld, Jens F., Holst, Jens J., Hovind, Peter, Jensen, Boye L., Bülow, Jens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413881/ https://www.ncbi.nlm.nih.gov/pubmed/32770661 http://dx.doi.org/10.14814/phy2.14519

Ejemplares similares

GIP-induced vasodilation in human adipose tissue involves capillary recruitment
por: Asmar, Meena, et al.
Publicado: (2019)

Glucagon‐like peptide‐1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men
por: Asmar, Ali, et al.
Publicado: (2017)

Glucose-Dependent Insulinotropic Polypeptide May Enhance Fatty Acid Re-esterification in Subcutaneous Abdominal Adipose Tissue in Lean Humans
por: Asmar, Meena, et al.
Publicado: (2010)

Fructose stimulates GLP-1 but not GIP secretion in mice, rats, and humans
por: Kuhre, Rune E., et al.
Publicado: (2014)

CCK‐1 and CCK‐2 receptor agonism do not stimulate GLP‐1 and neurotensin secretion in the isolated perfused rat small intestine or GLP‐1 and PYY secretion in the rat colon
por: Modvig, Ida M., et al.
Publicado: (2020)

The Antiresorptive Effect of GIP, But Not GLP‐2, Is Preserved in Patients With Hypoparathyroidism—A Randomized Crossover Study
por: Skov‐Jeppesen, Kirsa, et al.
Publicado: (2021)

Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma
por: Andersen, Ulrik Ø, et al.
Publicado: (2020)

What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?
por: Holst, Jens Juul
Publicado: (2021)

Abnormal gastric morphology and function in CCK-B/gastrin receptor-deficient mice.
por: Rindi, G., et al.
Publicado: (1998)

Gastrin and the Moderate Hypergastrinemias
por: Rehfeld, Jens F.
Publicado: (2021)

Effects of Manipulating Circulating Bile Acid Concentrations on Postprandial GLP-1 Secretion and Glucose Metabolism After Roux-en-Y Gastric Bypass
por: Jonsson, Isabella, et al.
Publicado: (2021)

Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats
por: Baldassano, Sara, et al.
Publicado: (2019)

Premises for Cholecystokinin and Gastrin Peptides in Diabetes Therapy
por: Rehfeld, Jens F
Publicado: (2019)

Postprandial Diabetic Glucose Tolerance Is Normalized by Gastric Bypass Feeding as Opposed to Gastric Feeding and Is Associated With Exaggerated GLP-1 Secretion: A case report
por: Dirksen, Carsten, et al.
Publicado: (2010)

Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell Function
por: Kielgast, Urd, et al.
Publicado: (2011)

Regulation of mammalian gastrin/CCK receptor (CCK2R) expression in vitro and in vivo
por: Ashurst, H Louise, et al.
Publicado: (2008)

Radiolabeled CCK/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors
por: Roosenburg, Susan, et al.
Publicado: (2010)

Postprandial levels of GLP-1, GIP and glucagon after 2 years of weight loss with a Paleolithic diet: a randomised controlled trial in healthy obese women
por: Otten, Julia, et al.
Publicado: (2019)

Effect of Age on Blood Glucose and Plasma Insulin, Glucagon, Ghrelin, CCK, GIP, and GLP-1 Responses to Whey Protein Ingestion
por: Giezenaar, Caroline, et al.
Publicado: (2017)

The Role of Gastrin and CCK Receptors in Pancreatic Cancer and other Malignancies
por: Smith, Jill P., et al.
Publicado: (2016)

Pharmacokinetics of exogenous GIP(1-42) in C57Bl/6 mice; Extremely rapid degradation but marked variation between available assays
por: Boer, Geke Aline, et al.
Publicado: (2021)

GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes
por: Mentis, Nikolaos, et al.
Publicado: (2011)

Sweet Taste Receptor Activation in the Gut Is of Limited Importance for Glucose-Stimulated GLP-1 and GIP Secretion
por: Saltiel, Monika Y., et al.
Publicado: (2017)

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
por: Willard, Francis S., et al.
Publicado: (2020)

Difference in postprandial GLP-1 response despite similar glucose kinetics after consumption of wheat breads with different particle size in healthy men
por: Eelderink, Coby, et al.
Publicado: (2016)

The blunted effect of glucose-dependent insulinotropic polypeptide in subcutaneous abdominal adipose tissue in obese subjects is partly reversed by weight loss
por: Asmar, M, et al.
Publicado: (2016)

GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1α Mutation Carriers
por: Christensen, Alexander S., et al.
Publicado: (2020)

A GLP-1:CCK fusion peptide harnesses the synergistic effects on metabolism of CCK-1 and GLP-1 receptor agonism in mice
por: Hornigold, David C., et al.
Publicado: (2018)

Comparative biodistribution of 12 (111)In-labelled gastrin/CCK2 receptor-targeting peptides
por: Laverman, Peter, et al.
Publicado: (2011)

Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men
por: Matikainen, Niina, et al.
Publicado: (2016)

The effect of DPP-4-protected GLP-1 (7–36) on coronary microvascular function in obese adults
por: Nilsson, Malin, et al.
Publicado: (2019)

What is Diabetes Remission?
por: Holst, Jens J., et al.
Publicado: (2021)

Effect of Meal Texture on Postprandial Glucose Excursions and Gut Hormones After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy
por: Hedbäck, Nora, et al.
Publicado: (2022)

GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
por: Holst, Jens Juul, et al.
Publicado: (2020)

Glucagon-Like Peptide 2 Inhibits Postprandial Gallbladder Emptying in Man: A Randomized, Double-Blinded, Crossover Study
por: Hansen, Nina L., et al.
Publicado: (2020)

The Role of GIP in the Regulation of GLP-1 Satiety and Nausea
por: Hayes, Matthew R., et al.
Publicado: (2021)

GIP and GLP‐1, the two incretin hormones: Similarities and differences
por: Seino, Yutaka, et al.
Publicado: (2010)

GLP1 and GIP are involved in the action of synbiotics in broiler chickens
por: Kolodziejski, Pawel Antoni, et al.
Publicado: (2018)

Searching for the physiological role of glucose‐dependent insulinotropic polypeptide
por: Holst, Jens Juul, et al.
Publicado: (2016)

GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report
por: Iepsen, Eva W., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n3jrudg3cuu88q2knj533peo9p